Anika Therapeutics, Inc. (NASDAQ: ANIK) Stock Competitors & Peer Comparison

Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANIK stands at 179.5M. In comparison, ALC has a market cap of 35.6B. Regarding current trading prices, ANIK is priced at $13.40 on the NASDAQ, while ALC trades at $74.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANIK currently has a P/E ratio of 27.35, whereas ALC's P/E ratio is 23.31. In terms of profitability, ANIK's ROE is -0.01%, compared to ALC's ROE of +0.03%. Regarding short-term risk, ANIK is more volatile compared to ALC. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check ALC's competition here

Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANIK stands at 179.5M. In comparison, STE has a market cap of 25.7B. Regarding current trading prices, ANIK is priced at $13.40 on the NASDAQ, while STE trades at $264.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANIK currently has a P/E ratio of 27.35, whereas STE's P/E ratio is 25.37. In terms of profitability, ANIK's ROE is -0.01%, compared to STE's ROE of +0.11%. Regarding short-term risk, ANIK is more volatile compared to STE. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check STE's competition here

Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANIK stands at 179.5M. In comparison, MLAB has a market cap of 781.3M. Regarding current trading prices, ANIK is priced at $13.40 on the NASDAQ, while MLAB trades at $139.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANIK currently has a P/E ratio of 27.35, whereas MLAB's P/E ratio is 14.03. In terms of profitability, ANIK's ROE is -0.01%, compared to MLAB's ROE of +0.04%. Regarding short-term risk, ANIK is more volatile compared to MLAB. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check MLAB's competition here

Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANIK stands at 179.5M. In comparison, QDEL has a market cap of 736.9M. Regarding current trading prices, ANIK is priced at $13.40 on the NASDAQ, while QDEL trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANIK currently has a P/E ratio of 27.35, whereas QDEL's P/E ratio is 8.01. In terms of profitability, ANIK's ROE is -0.01%, compared to QDEL's ROE of -0.20%. Regarding short-term risk, ANIK is less volatile compared to QDEL. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check QDEL's competition here

Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANIK stands at 179.5M. In comparison, MOBI has a market cap of 438.4M. Regarding current trading prices, ANIK is priced at $13.40 on the NASDAQ, while MOBI trades at $13.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANIK currently has a P/E ratio of 27.35, whereas MOBI's P/E ratio is -4.45. In terms of profitability, ANIK's ROE is -0.01%, compared to MOBI's ROE of -23.36%. Regarding short-term risk, ANIK is less volatile compared to MOBI. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check MOBI's competition here

Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANIK stands at 179.5M. In comparison, SI has a market cap of 432.9M. Regarding current trading prices, ANIK is priced at $13.40 on the NASDAQ, while SI trades at $20.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANIK currently has a P/E ratio of 27.35, whereas SI's P/E ratio is -11.96. In terms of profitability, ANIK's ROE is -0.01%, compared to SI's ROE of -0.26%. Regarding short-term risk, ANIK is more volatile compared to SI. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check SI's competition here

Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANIK stands at 179.5M. In comparison, MASS has a market cap of 405M. Regarding current trading prices, ANIK is priced at $13.40 on the NASDAQ, while MASS trades at $9.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANIK currently has a P/E ratio of 27.35, whereas MASS's P/E ratio is -16.23. In terms of profitability, ANIK's ROE is -0.01%, compared to MASS's ROE of -0.17%. Regarding short-term risk, ANIK is less volatile compared to MASS. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check MASS's competition here

Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANIK stands at 179.5M. In comparison, BWAY has a market cap of 396.5M. Regarding current trading prices, ANIK is priced at $13.40 on the NASDAQ, while BWAY trades at $10.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANIK currently has a P/E ratio of 27.35, whereas BWAY's P/E ratio is 25.68. In terms of profitability, ANIK's ROE is -0.01%, compared to BWAY's ROE of +0.13%. Regarding short-term risk, ANIK is less volatile compared to BWAY. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check BWAY's competition here

Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANIK stands at 179.5M. In comparison, LAB has a market cap of 279.3M. Regarding current trading prices, ANIK is priced at $13.40 on the NASDAQ, while LAB trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANIK currently has a P/E ratio of 27.35, whereas LAB's P/E ratio is -10.11. In terms of profitability, ANIK's ROE is -0.01%, compared to LAB's ROE of -0.08%. Regarding short-term risk, ANIK is less volatile compared to LAB. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check LAB's competition here

Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANIK stands at 179.5M. In comparison, EDAP has a market cap of 178.2M. Regarding current trading prices, ANIK is priced at $13.40 on the NASDAQ, while EDAP trades at $4.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANIK currently has a P/E ratio of 27.35, whereas EDAP's P/E ratio is -5.80. In terms of profitability, ANIK's ROE is -0.01%, compared to EDAP's ROE of -2.41%. Regarding short-term risk, ANIK is less volatile compared to EDAP. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check EDAP's competition here

Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANIK stands at 179.5M. In comparison, TRIB has a market cap of 124.7M. Regarding current trading prices, ANIK is priced at $13.40 on the NASDAQ, while TRIB trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANIK currently has a P/E ratio of 27.35, whereas TRIB's P/E ratio is -0.10. In terms of profitability, ANIK's ROE is -0.01%, compared to TRIB's ROE of +0.49%. Regarding short-term risk, ANIK is less volatile compared to TRIB. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check TRIB's competition here

Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANIK stands at 179.5M. In comparison, APYX has a market cap of 118.4M. Regarding current trading prices, ANIK is priced at $13.40 on the NASDAQ, while APYX trades at $2.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANIK currently has a P/E ratio of 27.35, whereas APYX's P/E ratio is -14.05. In terms of profitability, ANIK's ROE is -0.01%, compared to APYX's ROE of -0.71%. Regarding short-term risk, ANIK is less volatile compared to APYX. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check APYX's competition here

Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANIK stands at 179.5M. In comparison, SKIN has a market cap of 106.3M. Regarding current trading prices, ANIK is priced at $13.40 on the NASDAQ, while SKIN trades at $16.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANIK currently has a P/E ratio of 27.35, whereas SKIN's P/E ratio is -74.14. In terms of profitability, ANIK's ROE is -0.01%, compared to SKIN's ROE of -0.32%. Regarding short-term risk, ANIK is less volatile compared to SKIN. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check SKIN's competition here

Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANIK stands at 179.5M. In comparison, NYXH has a market cap of 91.6M. Regarding current trading prices, ANIK is priced at $13.40 on the NASDAQ, while NYXH trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANIK currently has a P/E ratio of 27.35, whereas NYXH's P/E ratio is -0.36. In terms of profitability, ANIK's ROE is -0.01%, compared to NYXH's ROE of -1.57%. Regarding short-term risk, ANIK is more volatile compared to NYXH. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check NYXH's competition here

Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANIK stands at 179.5M. In comparison, MDAI has a market cap of 41.8M. Regarding current trading prices, ANIK is priced at $13.40 on the NASDAQ, while MDAI trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANIK currently has a P/E ratio of 27.35, whereas MDAI's P/E ratio is -2.89. In terms of profitability, ANIK's ROE is -0.01%, compared to MDAI's ROE of +1.01%. Regarding short-term risk, ANIK is less volatile compared to MDAI. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check MDAI's competition here

Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANIK stands at 179.5M. In comparison, BEAT has a market cap of 22.3M. Regarding current trading prices, ANIK is priced at $13.40 on the NASDAQ, while BEAT trades at $0.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANIK currently has a P/E ratio of 27.35, whereas BEAT's P/E ratio is -0.78. In terms of profitability, ANIK's ROE is -0.01%, compared to BEAT's ROE of -4.03%. Regarding short-term risk, ANIK is less volatile compared to BEAT. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check BEAT's competition here

Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANIK stands at 179.5M. In comparison, ITOC has a market cap of 13.5M. Regarding current trading prices, ANIK is priced at $13.40 on the NASDAQ, while ITOC trades at $1.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANIK currently has a P/E ratio of 27.35, whereas ITOC's P/E ratio is -0.47. In terms of profitability, ANIK's ROE is -0.01%, compared to ITOC's ROE of -0.60%. Regarding short-term risk, ANIK is less volatile compared to ITOC. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check ITOC's competition here

Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANIK stands at 179.5M. In comparison, DRIO has a market cap of 12.3M. Regarding current trading prices, ANIK is priced at $13.40 on the NASDAQ, while DRIO trades at $1.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANIK currently has a P/E ratio of 27.35, whereas DRIO's P/E ratio is -0.22. In terms of profitability, ANIK's ROE is -0.01%, compared to DRIO's ROE of +0.95%. Regarding short-term risk, ANIK is less volatile compared to DRIO. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check DRIO's competition here

Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANIK stands at 179.5M. In comparison, MDAIW has a market cap of 12.2M. Regarding current trading prices, ANIK is priced at $13.40 on the NASDAQ, while MDAIW trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANIK currently has a P/E ratio of 27.35, whereas MDAIW's P/E ratio is -1.08. In terms of profitability, ANIK's ROE is -0.01%, compared to MDAIW's ROE of +1.01%. Regarding short-term risk, ANIK is less volatile compared to MDAIW. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check MDAIW's competition here

Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANIK stands at 179.5M. In comparison, BEATW has a market cap of 6.6M. Regarding current trading prices, ANIK is priced at $13.40 on the NASDAQ, while BEATW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANIK currently has a P/E ratio of 27.35, whereas BEATW's P/E ratio is -0.02. In terms of profitability, ANIK's ROE is -0.01%, compared to BEATW's ROE of -4.03%. Regarding short-term risk, ANIK is less volatile compared to BEATW. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check BEATW's competition here

Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANIK stands at 179.5M. In comparison, QTEXW has a market cap of 3.5M. Regarding current trading prices, ANIK is priced at $13.40 on the NASDAQ, while QTEXW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANIK currently has a P/E ratio of 27.35, whereas QTEXW's P/E ratio is -0.01. In terms of profitability, ANIK's ROE is -0.01%, compared to QTEXW's ROE of N/A. Regarding short-term risk, ANIK is less volatile compared to QTEXW. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check QTEXW's competition here

Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANIK stands at 179.5M. In comparison, WOK has a market cap of 2.9M. Regarding current trading prices, ANIK is priced at $13.40 on the NASDAQ, while WOK trades at $1.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANIK currently has a P/E ratio of 27.35, whereas WOK's P/E ratio is N/A. In terms of profitability, ANIK's ROE is -0.01%, compared to WOK's ROE of -0.19%. Regarding short-term risk, ANIK is less volatile compared to WOK. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check WOK's competition here

Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANIK stands at 179.5M. In comparison, FEED has a market cap of 951.4K. Regarding current trading prices, ANIK is priced at $13.40 on the NASDAQ, while FEED trades at $1.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANIK currently has a P/E ratio of 27.35, whereas FEED's P/E ratio is -0.15. In terms of profitability, ANIK's ROE is -0.01%, compared to FEED's ROE of -0.60%. Regarding short-term risk, ANIK is less volatile compared to FEED. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check FEED's competition here

Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANIK stands at 179.5M. In comparison, TIVC has a market cap of 279.2K. Regarding current trading prices, ANIK is priced at $13.40 on the NASDAQ, while TIVC trades at $0.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANIK currently has a P/E ratio of 27.35, whereas TIVC's P/E ratio is -0.04. In terms of profitability, ANIK's ROE is -0.01%, compared to TIVC's ROE of -1.65%. Regarding short-term risk, ANIK is less volatile compared to TIVC. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check TIVC's competition here